Clinical Trials Logo

Environment clinical trials

View clinical trials related to Environment.

Filter by:
  • None
  • Page 1

NCT ID: NCT06193005 Not yet recruiting - Inflammation Clinical Trials

Correlation Between Psychological Resilience and Genetic, Inflammatory Indicators

Start date: January 1, 2024
Phase:
Study type: Observational

The goal of this observational study is to evaluate and analyze the influencing factors of the adaptive ability of young people, explore the impact of the interaction of environment and gene on the psychological adaptive ability of young people, incorporate the prediction model of the dynamic change of adaptive ability, build a standardized norm of young people's adaptive ability, and form a grading reference standard system. The main questions it aims to answer are: - What are most important influencing factors for the adaptive ability of young people? - How the environment and gene interact with each other on the psychological adaptive ability of young people? - Can we build a prediction model of the dynamic change of adaptive ability and form a grading reference standard system? Participants will support us with basic information data, adaptive ability assessment data, genetic testing data, brain image scanning data, and inflammatory indicators data. Then subjects were divided into very low adaptive group, low adaptive group, high adaptive group and very high adaptive group according to the quartile of adaptive ability score. And the statistical analysis will be performed by the data analyst.

NCT ID: NCT05350761 Recruiting - Cancer Clinical Trials

Rare Tumors and Cancer Predisposition in Individuals and Families

Start date: March 10, 2023
Phase:
Study type: Observational

Background: Some people may be prone to develop cancer for many reasons. Factors that affect their risk include the genes they inherit and the environment they live and work in. Researchers want to learn more about the natural history of cancer. Objective: To understand how genes and environmental factors can cause tumors and related conditions. Eligibility: People of any age who: Have tumors of an unusual type, pattern, or number Have a family member with a history of cancer Have been exposed to other factors that may increase their risk of cancer Design: This study does not involve treatment. Participants will answer questions about their personal and family medical history. They will give permission for researchers to see their medical records. Participants may be invited to the NIH Clinical Center for a physical exam. They may give samples including saliva, cheek cells, blood, urine, skin, and/or hair. Participants with cancer may give bone marrow. A needle will be used to remove a small sample of bone marrow from their hip bone. Participants may have a biopsy of their tumor. Participants may have other exams: Dental Ear, nose, and throat Eye Hearing Heart function and structure Participants with cancer may undergo more exams: A test of how much energy their body uses when resting A sleep study with a test that measures brain electrical activity. They will have sensors attached to their body while they sleep overnight in a lab. Imaging scans, such as CT, MRI, a test to measure how dense their bones are (DEXA), and ultrasound. Participants will have their genes tested. A counsellor will help them understand the results. Participants will be followed until at least 2035....

NCT ID: NCT05158010 Completed - Health Behavior Clinical Trials

Advancing Tools for Human Early Lifecourse Exposome Research and Translation- Adolescence Follow-up of the HELIX Subcohort

ATHLETE
Start date: November 10, 2021
Phase: N/A
Study type: Interventional

ATHLETE will set up a prospective Europe-wide exposome cohort covering the first 2 decades of the life course, which will integrate data on the external, chemical, physical,behavioral, and social domains of the exposome, as well as on health outcomes and biological omics responses, from preconception until adolescence. As part of ATHLETE, the investigators will follow up a unique existing exposome cohort into adolescence (the HELIX Subcohort).

NCT ID: NCT04611945 Completed - Mood Clinical Trials

Westlake Sailing Cohort

Start date: November 10, 2020
Phase:
Study type: Observational

Little is known about the dynamic change of human microbiome in different body sites including skin, mouth and gut during sailing. The present study aims to reveal the change of human microbiome in response to the sailing environment in a 1-month period, and its implication for human health.

NCT ID: NCT00339274 Completed - Environment Clinical Trials

International Cooperation for Post-Cherynobyl NIS Thyroid Tissue and Data Banks

Start date: October 14, 1999
Phase: N/A
Study type: Observational

The large number of thyroid tumors that have occurred in areas exposed to high levels of fallout from the Chernobyl accident raise problems of public health importance, or regulatory importance, and of scientific importance. The over-riding priority must go to matters such as diagnosis, treatment of those affected and prevention, and International Agencies are giving financial and material help in these areas. However providing the needs of the patient are not compromised, it is very important to ensure that information that may be of value to the health of future generations is not lost. International agencies are again providing financial support for a variety of joint studies, some of which are based on studies of tissues from thyroid operations carried out as part of treatment, and not required for the initial diagnosis on which treatment is based. An international coordinated approach to this problem is not in place to help Belarus, the Russian Federation and Ukraine to establish their own comprehensive thyroid tissue and data banks and to ensure that tissue and nucleic acids are used to contribute to the understanding of the consequences of the Chernobyl accident. This project has the support of the Governments of Belarus, the Russian Federation and Ukraine and the National Cancer Institute of the USA, (NCI), the European Commission (EC), the Sasakawa Memorial Health Foundation of Japan (SMHF) and the World Health Organization (WHO) have agreed to cooperate in supporting this project.

NCT ID: NCT00001163 Active, not recruiting - Cancer Clinical Trials

Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Cancer

Start date: April 2, 1985
Phase:
Study type: Observational

This is a clinical, epidemiologic, genetic, and laboratory study of individuals and families at high risk of cancer and selected tumors to investigate the genetic susceptibility and environmental exposures which may alter cancer risk. Families with multiple members who have an unusual pattern or number of cancers or tumors are evaluated clinically. This evaluation is specific for the type of cancer or tumor predominant in the family in order to determine the affection status of each individual for genetic epidemiologic studies. Genetic and environmental risk factor information specific for the tumor type is obtained. Individuals with, or at high risk of, cancer because of their personal, familial, or environmental histories are identified by healthcare worker referral or by personal inquiry. Relevant etiologic risk factor information is documented through review of pathology specimens and medical, vital, and genealogical records. Selected individuals and family members are asked to complete questionnaires and to undergo clinical evaluations specific for the tumor of interest. They are also asked to donate biologic specimens to be used in the search for cancer etiology and mechanisms of carcinogenesis. No therapy beyond counseling and education for cancer prevention, risk reduction, and early detection will be given. Genetic testing for tumor susceptibility gene(s) mutations and risk notification will be offered to study participants for whom a specific mutation predictive of disease has been identified in his/her family. This testing will only be offered when reasonable individual cancer risk estimates can be delivered, and only to those participants who choose to know their individual genetic status after appropriate education and counseling. The testing will be conducted exclusively in Clinical Laboratory Improvement Amendments (CLIA)-licensed laboratories. Genetic testing and risk notification are entirely optional and do not affect participation in other aspects of the protocol. A separate consent procedure and consent form will be used for genetic testing and risk notification related to these specific genes. Once enrolled, study participants are monitored prospectively for the development of outcomes of interest, typically by means of periodic mail or telephone contact. In selected instances, subjects may return to the Clinical Center periodically for study-specific follow-up examinations. Although we do not offer specific anti-cancer therapy as part of this protocol, we provide assistance to insure that study participants who require treatment for tumor-related problems that develop during the course of the study are referred to appropriate healthcare providers. We remain available to study participants and their healthcare providers for advice and consultation related to the management of familial cancer/tumor predisposition.